MARKET

TCRX

TCRX

Tscan Therapeutics, Inc.
NASDAQ
0.1606
-0.0074
-4.40%
After Hours: 0.1640 +0.0034 +2.12% 19:49 11/13 EST
OPEN
0.1740
PREV CLOSE
0.1680
HIGH
0.1749
LOW
0.1603
VOLUME
227.69K
TURNOVER
--
52 WEEK HIGH
1.470
52 WEEK LOW
0.1603
MARKET CAP
10.89M
P/E (TTM)
-0.1813
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), TScan Therapeutics (TCRX) and AbSci (ABSI)
TipRanks · 1d ago
TScan Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Corporate Update
NASDAQ · 1d ago
TScan Therapeutics Q3 Loss Narrows To $33.1 Mln; Pivots Focus To Solid Tumor Program
NASDAQ · 2d ago
TScan Therapeutics GAAP EPS of -$0.25 misses by $0.06, revenue of $0.59M beats by $0.12M
Seeking Alpha · 2d ago
TScan Therapeutics Q3 EPS $(0.25) Misses $(0.19) Estimate, Sales $586.000K Beat $459.000K Estimate
Benzinga · 2d ago
*TScan Therapeutics 3Q Loss $33.1M >TCRX
Dow Jones · 2d ago
*TScan Therapeutics 3Q Rev $600,000 >TCRX
Dow Jones · 2d ago
Press Release: TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 2d ago
More
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company is advancing two therapeutics candidates through IND-enabling studies to treat solid tumors using in vivo-engineered TCR-T cells. In addition, the Company is seeking partnerships for its hematologic malignancies and autoimmune programs. Its construct consists of two proprietary components: dual-targeting antibodies that direct the virus to cytotoxic and helper T-cells and mediate T cell activation, and a non-targeting fusogen that mediates entry exclusively to T-cells. Its hematology program is designed to address patients who are diagnosed with hematologic malignancies and can benefit from undergoing allogeneic transplantation. Its TSC-102-A01 and TSC-102-A03 are allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45.

Webull offers Tscan Therapeutics Inc stock information, including NASDAQ: TCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TCRX stock methods without spending real money on the virtual paper trading platform.